pr_newswire_finance · 2026-10-22
Oral presentation will feature preclinical research evaluating Tikva's armored allogeneic CD19 CAR T-cell therapy as a potential lymphodepletion-free approach for systemic lupus erythematosus SINGAPORE, Oct. 22, 2026 /PRNewswire/ -- Tikva Allocell Pte. Ltd. ("Tikva"), a biotechnology...
Sector coverage: Real Estate · REIT - Mortgage · Industrials · Rental & Leasing Services
Read the original at pr_newswire_finance ↗
Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.
Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。